CY1110008T1 - Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c - Google Patents
Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας cInfo
- Publication number
- CY1110008T1 CY1110008T1 CY20101100355T CY101100355T CY1110008T1 CY 1110008 T1 CY1110008 T1 CY 1110008T1 CY 20101100355 T CY20101100355 T CY 20101100355T CY 101100355 T CY101100355 T CY 101100355T CY 1110008 T1 CY1110008 T1 CY 1110008T1
- Authority
- CY
- Cyprus
- Prior art keywords
- c6alkyl
- c3alkylene
- usitis
- virus
- crz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ενώσεις του τύπου (I), και Ν-οξείδια, άλατα, και στερεοϊσομερή αυτών όπου Α είναι OR1, NHS(=0)PR2. όπου R1 είναι υδρογόνο, C1-C6αλκυλ, C0-C3αλκυλενοκαρβοκυκλυλ, C0-C3αλκυλενο-ετεροκυκλυλ· R2 είναι C1-C6αλκυλ, C0-C3αλκυλεvoκαρβoκυκλυλ, C0-C3αλκυλενοετεροκυκλυλ∙ p είναι ανεξάρτητα 1 ή 2· n είναι 3, 4, 5 ή 6· -----δηλώνει έναν προαιρετικό διπλό δεσμό∙ L είναι Ν ή CRz· Rz είναι Η ή σχηματίζει ένα διπλό δεσμό με τον άνθρακα που φέρει αστερίσκο· Rq είναι Η ή όταν το L είναι CRz, το Rq μπορεί επίσης να είναι C1-C6αλκυλ· Rr είναι κουιναζολινυλ, προαιρετικά υποκατεστημένο μ' ένα, δύο ή τρεις υποκατάστατες που καθένας ανεξάρτητα επιλέγεται από C1-C6αλκυλ, C1-C6αλκοξυ, υδροξυλ, αλο, αλοC1-C6αλκυλ, αμινο, μονο- ή διαλκυλαμινο, μονο- ή διαλκυλαμινοκαρβονυλ, C1-C6αλκυλκαρβονυλαμινο, C0-C3αλκυλενοκαρβοκυκλυλ και C0-C3αλκυλετεροκυκλυλ· R5 είναι υδρογόνο, C1-C6αλκυλ, C1-C6αλκοξυC1-C6αλκυλ ή C3-C7cκυκλοαλκυλ· R6 είναι υδρογόνο, C1-C6αλκυλ, C1-C6αλκοξυ, C0-C3αλκυλενοκαρβοκυκλυλ, C0-C3αλκυλενο-ετεροκυκλυλ, υδροξυ, βρωμο, χλωρό ή φθορο που χρησιμεύουν στη θεραπεία ή την προφύλαξη flaviviral λοιμώξεων όπως HCV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107057 | 2005-07-29 | ||
EP06113097 | 2006-04-25 | ||
EP06764268A EP1912981B1 (en) | 2005-07-29 | 2006-07-28 | Macrocyclic inhibitors of hepatitis c virus |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110008T1 true CY1110008T1 (el) | 2015-01-14 |
Family
ID=37708968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100355T CY1110008T1 (el) | 2005-07-29 | 2010-04-20 | Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c |
Country Status (32)
Country | Link |
---|---|
US (1) | US7659245B2 (el) |
EP (1) | EP1912981B1 (el) |
JP (1) | JP5230418B2 (el) |
KR (1) | KR101083631B1 (el) |
AP (1) | AP2585A (el) |
AR (1) | AR057702A1 (el) |
AT (1) | ATE455775T1 (el) |
AU (1) | AU2006274866B2 (el) |
BR (1) | BRPI0614153A2 (el) |
CA (1) | CA2617103C (el) |
CY (1) | CY1110008T1 (el) |
DE (1) | DE602006011905D1 (el) |
DK (1) | DK1912981T3 (el) |
EA (1) | EA014188B1 (el) |
ES (1) | ES2339702T3 (el) |
GT (1) | GT200600343A (el) |
HK (1) | HK1116488A1 (el) |
HR (1) | HRP20100209T1 (el) |
IL (1) | IL188320A (el) |
ME (1) | ME01454B (el) |
MY (1) | MY151026A (el) |
NO (1) | NO20081075L (el) |
NZ (1) | NZ564540A (el) |
PE (1) | PE20070343A1 (el) |
PL (1) | PL1912981T3 (el) |
PT (1) | PT1912981E (el) |
RS (1) | RS51227B (el) |
SI (1) | SI1912981T1 (el) |
SV (1) | SV2008002641A (el) |
TW (1) | TWI387597B (el) |
UY (1) | UY29704A1 (el) |
WO (1) | WO2007014927A2 (el) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AR048401A1 (es) | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
AR057704A1 (es) | 2005-07-29 | 2007-12-12 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto |
EP1912997B1 (en) | 2005-07-29 | 2011-09-14 | Tibotec Pharmaceuticals | Macrocyclic inhibitors of hepatitis c virus |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
MX2008004754A (es) | 2005-10-11 | 2009-03-02 | Intermune Inc | Compuestos y metodos para inhibir la replicacion viral de hepatitis c. |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR101512477B1 (ko) | 2006-07-13 | 2015-04-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드 |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20090079881A (ko) * | 2006-11-17 | 2009-07-22 | 티보텍 파마슈티칼즈 리미티드 | C형 간염 바이러스의 마크로사이클릭 억제제 |
PL2121674T3 (pl) * | 2007-02-01 | 2010-10-29 | Janssen Sciences Ireland Uc | Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV |
EP2118091B1 (en) * | 2007-02-08 | 2015-04-15 | Janssen Sciences Ireland UC | Pyrimidine substituted macrocyclic hcv inhibitors |
ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
CA2700383A1 (en) * | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
JPWO2009084695A1 (ja) | 2007-12-28 | 2011-05-19 | カルナバイオサイエンス株式会社 | 2−アミノキナゾリン誘導体 |
WO2009117594A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PL2364309T3 (pl) | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals Inc | Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
DK2401272T3 (en) | 2009-02-27 | 2017-02-27 | Janssen Pharmaceuticals Inc | AMORF SALT OF A MACROCYCLIC INHIBITOR OF HCV |
WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
EP2435419A1 (en) * | 2009-05-29 | 2012-04-04 | Syngenta Participations AG | Substituted quinazolines as fungicides |
AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
PE20140039A1 (es) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina |
MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2012360905B2 (en) | 2011-12-28 | 2017-04-27 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
BR112015008171B1 (pt) * | 2012-10-15 | 2021-01-19 | Albemarle Corporation | processos para a síntese de 2-amino-4,6-dimetoxibenzamida e de outros compostos de benzamida |
DK2909205T3 (en) | 2012-10-19 | 2017-03-06 | Bristol Myers Squibb Co | 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
KR20040099425A (ko) | 2002-04-11 | 2004-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4프로테아제의 억제제 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
KR100940619B1 (ko) * | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
US20040180815A1 (en) * | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
EP1629000B1 (en) * | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
AR048401A1 (es) * | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
DK1912996T3 (da) * | 2005-07-29 | 2012-09-17 | Janssen R & D Ireland | Makrocykliske inhibitorer af hepatitis C-virus |
JP2009502845A (ja) * | 2005-07-29 | 2009-01-29 | メディヴィル・アクチボラグ | C型肝炎ウイルスの大環状インヒビター |
ES2456617T3 (es) * | 2005-07-29 | 2014-04-23 | Janssen R&D Ireland | Inhibidores macrocíclicos del virus de la hepatitis C |
-
2006
- 2006-07-26 PE PE2006000903A patent/PE20070343A1/es not_active Application Discontinuation
- 2006-07-28 AT AT06764268T patent/ATE455775T1/de active
- 2006-07-28 KR KR1020087004894A patent/KR101083631B1/ko not_active IP Right Cessation
- 2006-07-28 EA EA200800482A patent/EA014188B1/ru not_active IP Right Cessation
- 2006-07-28 DK DK06764268.6T patent/DK1912981T3/da active
- 2006-07-28 BR BRPI0614153-6A patent/BRPI0614153A2/pt not_active Application Discontinuation
- 2006-07-28 PT PT06764268T patent/PT1912981E/pt unknown
- 2006-07-28 TW TW095127585A patent/TWI387597B/zh not_active IP Right Cessation
- 2006-07-28 RS RSP-2010/0183A patent/RS51227B/sr unknown
- 2006-07-28 AU AU2006274866A patent/AU2006274866B2/en not_active Ceased
- 2006-07-28 ES ES06764268T patent/ES2339702T3/es active Active
- 2006-07-28 PL PL06764268T patent/PL1912981T3/pl unknown
- 2006-07-28 US US11/995,900 patent/US7659245B2/en not_active Expired - Fee Related
- 2006-07-28 ME MEP-2012-119A patent/ME01454B/me unknown
- 2006-07-28 SI SI200630627T patent/SI1912981T1/sl unknown
- 2006-07-28 NZ NZ564540A patent/NZ564540A/en not_active IP Right Cessation
- 2006-07-28 GT GT200600343A patent/GT200600343A/es unknown
- 2006-07-28 CA CA2617103A patent/CA2617103C/en not_active Expired - Fee Related
- 2006-07-28 AP AP2008004306A patent/AP2585A/xx active
- 2006-07-28 JP JP2008523383A patent/JP5230418B2/ja not_active Expired - Fee Related
- 2006-07-28 DE DE602006011905T patent/DE602006011905D1/de active Active
- 2006-07-28 AR ARP060103303A patent/AR057702A1/es not_active Application Discontinuation
- 2006-07-28 WO PCT/EP2006/064822 patent/WO2007014927A2/en active Application Filing
- 2006-07-28 EP EP06764268A patent/EP1912981B1/en active Active
- 2006-07-28 UY UY29704A patent/UY29704A1/es unknown
- 2006-07-28 MY MYPI20063670 patent/MY151026A/en unknown
- 2006-07-29 SV SV2006002641A patent/SV2008002641A/es unknown
-
2007
- 2007-12-20 IL IL188320A patent/IL188320A/en not_active IP Right Cessation
-
2008
- 2008-02-29 NO NO20081075A patent/NO20081075L/no not_active Application Discontinuation
- 2008-06-20 HK HK08106903.5A patent/HK1116488A1/xx not_active IP Right Cessation
-
2010
- 2010-04-14 HR HR20100209T patent/HRP20100209T1/hr unknown
- 2010-04-20 CY CY20101100355T patent/CY1110008T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110008T1 (el) | Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c | |
CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
CY1109497T1 (el) | Παραγωγα θειοφενιου ως αντιβιοτικοι παραγοντες για λοιμωξη/μολυνση φλαβοϊου (flavivirus) | |
HK1112910A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
MA29774B1 (fr) | Utilisation de derives azabicyclo | |
HN2001000099A (es) | Nuevos derivados del fenil-propargiileter | |
CY1114001T1 (el) | Συντηγμενες ετεροκυκλικες ενωσεις χρησιμες ως ρυθμιστες κινασης | |
CY1109322T1 (el) | Παραγωγα προλινης και η χρηση τους ως αναστολεις διπεπτιδυλικης πεπτιδασης iv | |
IN2012DN00999A (el) | ||
DK1381366T3 (da) | Indol, azaindol og beslægtede heterocykliske amidopiperazinderivater | |
AU2003291885A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
CY1111628T1 (el) | Υποκατεστημενες ενωσεις δικυκλολακταμης | |
ATE398117T1 (de) | Verbindungen mit antibakteriellen und antiparasitischen eigenschaften | |
DE60227794D1 (de) | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon | |
NO20040100L (no) | Nye forbindelser som anti-inflammasjons, immunmodulerende og anti-proliferative midler | |
CY1115548T1 (el) | Ενωση κυκλικης αμινης και παραγων ελεγχου παρασιτων | |
DE602005009977D1 (de) | Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten | |
NO20054361D0 (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte | |
CY1114240T1 (el) | Παραγωγα σουλφοναμιδιου τετραϋδροϊσοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη | |
ATE472560T1 (de) | N-substituierte imide als polymerisatiosinitiatoren | |
MX2021011286A (es) | Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. | |
MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
MY136824A (en) | Substituted benzoxazinones and uses thereof | |
DE60302572D1 (de) | Insektizide amide mit stickstoffhaltigen kondensierten bizyklischen ringsystemen |